The FDA Changed the Hormone Therapy Warning. Here Is What It Actually Says.

July 29, 2026 · Last reviewed August 8, 2026

Written and reviewed by Rev. Dr. LaVeena B. Archers, PhD
Doctor of Natural Medicine · Board-certified in Holistic Functional Medicine and Functional Nutrition
Educational content only. Not medical advice, and never a substitute for your own care. Scope of practice.

The FDA asked the makers of menopausal hormone therapy products to remove statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning ^[1]. It did not ask them to remove cardiovascular disease and breast cancer from the Warnings and Precautions section of the label, and it left the boxed warning for endometrial cancer on systemic estrogen-alone products in place ^[1]. Those risks came out of the box. They did not come off the label, and little of the coverage said so.

You have probably seen a version of the headline by now: the FDA removed the breast cancer warning from hormone therapy, decades of fear overturned. The real change is narrower than that. So here is what the FDA actually said, in its own words, and what it did not say.

What did the FDA actually change?

The FDA asked the makers of hormone therapy products to remove language about the risk of cardiovascular disease, breast cancer and probable dementia from the boxed warning, and to make other safety-related labeling changes ^[1].

A boxed warning is the most prominent safety warning the FDA applies to a prescription drug ^[1]. It sits at the top of the label in a black border, which is where the nickname comes from. Putting a risk in that box is the agency's strongest way of saying pay attention to this.

So the change is real, and it is broad. The request covers all HRT products containing estrogen or progestogen, in all dose forms ^[1].

What did not change, and was not reported

Read this sentence from the FDA carefully, because little of the coverage included it:

FDA has not requested that drug sponsors remove the risks of cardiovascular disease and breast cancer from the Warnings and Precautions section of the labeling ^[1].

Those risks came out of the box. They did not come off the label.

That is a meaningfully different statement from the one the headlines made. The FDA has not concluded that hormone therapy carries no cardiovascular or breast cancer risk. Its stated rationale is that presenting those risks in its most severe format, applied broadly to every product and every woman, was deterring women who might benefit from treatment ^[1].

There is a second thing that stayed. The boxed warning for endometrial cancer on systemic estrogen-alone products remains in place, and the FDA specifically did not request its removal ^[1]. That warning matters for women with a uterus, which is precisely why progestogen is added alongside estrogen in that situation ^[1].

Where did the original warning come from?

To understand why the boxed warning is being revisited, it helps to know what produced it in the first place.

In 2002 the Women's Health Initiative stopped one of its arms early. It had randomized 16,608 postmenopausal women aged 50 to 79 to either combined estrogen plus progestin or placebo, and after an average of 5.2 years the monitoring board halted it because the results crossed a boundary for breast cancer and the overall balance of risks and benefits had tipped ^[2].

The finding reshaped women's medicine almost overnight. It is worth looking at the actual numbers, because very few women ever were shown them.

Per 10,000 women per year, the trial found 7 more coronary events, 8 more strokes, 8 more pulmonary embolisms and 8 more invasive breast cancers. It also found 6 fewer colorectal cancers and 5 fewer hip fractures ^[2].

Those are real harms and they should not be waved away. They are also small absolute numbers, and they were communicated to a generation of women as though they were enormous.

The breast cancer result is worth one more sentence. The hazard ratio was 1.26, with a 95% confidence interval running from 1.00 to 1.59 ^[2]. The lower edge of that interval sits exactly on 1.00, which is the value meaning no increased risk at all. The stroke and clot findings were on firmer statistical ground. The breast cancer signal, the one that did most of the frightening, was the least certain of them.

Why the age of the trial participants matters

Here is the mismatch that drove the reappraisal.

The Women's Health Initiative participants were aged 50 to 79, and a large share were well past menopause when they started treatment. The results were then applied to a different woman entirely: the fifty-one year old starting hormone therapy for symptoms in the first years after her final period.

Starting a hormone in a sixty-eight year old whose arteries have already been changing for two decades is not the same intervention as starting it in a woman at fifty-one, even when the tablet is identical. The trial answered one question. The warning was applied to another.

This is the same problem I keep writing about here in other forms. Evidence gathered in one group gets applied to a group it was never gathered in, and the mismatch does real damage in both directions.

The wider picture supports treating the transition as its own distinct window. The American Heart Association's scientific statement on menopause and cardiovascular risk describes the menopause transition as a period of accelerating cardiovascular risk, with adverse changes in body composition, lipids and vascular health, and identifies midlife as a critical window for early prevention ^[3]. That statement is about cardiovascular risk and prevention generally rather than an endorsement of any particular therapy, and I am not going to stretch it into one, because not stretching a source past what it says is the standard this site runs on.

What I am not telling you

I need to be plain about my own position here.

I am a Doctor of Natural Medicine. I do not prescribe, and hormone therapy is a prescription decision that belongs entirely between you and a qualified prescriber who knows your history, your family history, your cardiovascular and clotting risk, and whether you have a uterus.

Nothing on this page is a recommendation to start hormone therapy, and nothing here is a reason to stop something you are taking. If this news makes you want to revisit the question, the person to revisit it with is your prescriber.

What I can do is make sure you walk into that conversation with an accurate picture rather than a headline.

What should you ask your prescriber?

If the warning change is the reason you are reconsidering, these are the questions worth taking with you.

Ask what the risks are for you, given your own history, rather than for a population. The label change moved general risk statements out of a general box. It did not tell you anything about your own arteries.

Ask about timing, since how long it has been since your final period is part of the picture.

Ask which of the four types is being discussed, because systemic combined therapy, systemic estrogen alone, progestogen alone and topical vaginal estrogen are four different treatments ^[1], and their labels do not say the same things.

And ask what the plan is for reviewing it, rather than treating the decision as permanent in either direction.

The honest summary of the FDA change

The FDA concluded that its strongest warning format, applied bluntly to every woman and every product, was deterring women from treatment ^[1]. Reading that as more harm than good is a defensible call and, in my view, an overdue one.

It is not the same as deciding the risks were imaginary. The FDA left them in the label, kept the endometrial cancer box on estrogen-alone products, and asked for a more accurate presentation rather than a reassuring one ^[1].

Both of those things are true at once, and you were only told the first.

← All posts